Visual field defects and other ophthalmological disturbances associated with vigabatrin

Drug Safety

Volumn 24, Issue 5, 2001, Pages 385-404

  Spence, Sarah J ^a   Sankar, Raman ^a  

^a MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIGABATRIN;

COLOR VISION; CONVULSION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; OPHTHALMOSCOPY; PRIORITY JOURNAL; REVIEW; VISUAL ACUITY; VISUAL FIELD; VISUAL FIELD DEFECT;

ANTICONVULSANTS; EYE DISEASES; HUMANS; VIGABATRIN; VISUAL FIELDS;

EID: 0035025357     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200124050-00005     Document Type: Review

References (63)

1. Vigabatrin
2. Neuropathology of vigabatrin
3. Use of ex vivo magnetic resonance imaging to detect onset of vigabatrin-induced intramyelinic edema in canine brain
4. Effects of long term vigabatrin on somatosensory evoked potentials in epileptic patients
5. Neuropathologic findings in patients receiving long-term vigabatrin therapy for chronic intractable epilepsy
6. Neuropathology of a human hippocampus following long-term treatment with vigabatrin: Lack of microvacuoles
7. No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: Results of a multicenter study of somatosensory and visual evoked potentials
8. Low-dose vigabatrin (gamma-vinyl GABA)-induced damage in the immature rat brain
9. Effect of long-term vigabatfin administration on the immature rat brain
10. Severe persistent visual field constriction associated with vigabatrin
11. Outer retinal dysfunction in patients treated with vigabatrin
12. Symptomatic and asymptomatic visual loss in patients taking vigabatrin
13. Vigabatrin-associated retinal cone system dysfunction: Electroretinogram and ophthalmologic findings
14. Visual dysfunction in patients receiving vigabatrin: Clinical and electrophysiologic findings
15. Visual impairment in children with epilepsy treated with vigabatrin
16. Separating the retinal electrophysiologic effects of vigabatrin: Treatment versus field loss
17. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects
18. Visual field defects associated with vigabatrin therapy
19. Characteristics of a unique visual field defect attributed to vigabatrin
20. A controlled study of vigabatrin and visual abnormalities
21. Visual field defects in patients taking vigabatrin
22. Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions
23. Severe persistent visual field constriction associated with vigabatrin. Reaction might be dose dependent
24. Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing
25. Severe persistent visual field constriction associated with vigabatrin: Four possible explanations exist
26. Severe persistent visual field constriction associated with vigabatrin: Asymptomatic as well as symptomatic defects occur with vigabatrin
27. Study is needed of visual field defects associated with any long term antiepileptic drug
28. Visual field restriction with new antiepileptic medication
29. Visual field (VF) constriction: One case associated with progabide and phenobarbital and three cases of worsening preexisting VF defects in presence of vigabtrin
30. Vigabatrin associated visual field constriction
31. Viagabatrin-associated bilateral concentric visual field defects in four patients
32. Visual field constriction in children treated with vigabatrin
33. Reversibility of vigabratin-induced visual-field defect
34. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin
35. Visual function loss from vigabatrin: Effect of stopping the drug
36. Colour vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy
37. Contrast and glare sensitivity in epilepsy patients treated with vigabatrin or carbamazepine monotherapy compared with healthy volunteers
38. Vigabatrin in childhood epilepsy: A 5-year follow-up study
39. Vigabatrin induced optic neuropathy
40. Visual electrophysiological effect of a GABA transaminase blocker
41. Electroretinographic changes are not associated with loss of visual function in pediatric patients following treatment with vigabatrin
42. The effect of vigabatrin on visual function: Data from a long-term open-label add-on trial in patients with uncontrolled partial seizures
43. Vigabatrin and visual field loss
44. Severe persistent visual field constriction associated with vigabatrin. Benefit: Risk ratio must be calculated for individual patients
45. Visual field constriction is not limited to children treated with vigabatrin
46. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication
47. Vigabatrin and visual field defects: Is there a link
48. Constriction of the visual field in epilepsy patients taking vigabatrin and other antiepileptic drugs: A longitudinal study
49. Visual field defects under treatment with vigabatrin (VGB), carbamazepine (CBZ) and valproate (VPA): A prospective study
50. Possible retinotoxic effects of carbamazepine
51. Diazepam and its effects on visual fields
52. Severe visual-field constriction and side-effects of GABA-mimetic anti-epileptic agents
53. Absence of visual field defects in patients taking tiagabine
54. Lack of visual field defects with long-term use of tiagabine
55. Absence of concentric visual field defects in patients with initial tiagabine monotherapy
56. Tiagabine monotherapy in chronic partial epilepsy
57. Is visual impairment related to vigabatrin reversible
58. Recovery of visual field constriction following discontinuation of vigabatrin
59. Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin
60. Vigabatrin-associated retinal cone system dysfunction: Letters to the Editor, reply from the authors
61. The rabbit electroretinogram: Effect of GABA and its antagonists
62. Using the electroretinogram to detect and monitor retinal toxicity of anticonvulsants
63. Is the devil we know the lesser of two evils?. Vigabatrin and visual fields